INC Research Holdings Inc (INCR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
INC Research Holdings Inc stock (INCR) is currently trading at $0.75. INC Research Holdings Inc PS ratio (Price-to-Sales) is 0.49. Analyst consensus price target for INCR is $33.56. WallStSmart rates INCR as Sell.
- INCR PE ratio analysis and historical PE chart
- INCR PS ratio (Price-to-Sales) history and trend
- INCR intrinsic value — DCF, Graham Number, EPV models
- INCR stock price prediction 2025 2026 2027 2028 2029 2030
- INCR fair value vs current price
- INCR insider transactions and insider buying
- Is INCR undervalued or overvalued?
- INC Research Holdings Inc financial analysis — revenue, earnings, cash flow
- INCR Piotroski F-Score and Altman Z-Score
- INCR analyst price target and Smart Rating
INC Research Holdings Inc
📊 No data available
Try selecting a different time range
Smart Analysis
INC Research Holdings Inc (INCR) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
INC Research Holdings Inc (INCR) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
INC Research Holdings Inc (INCR) Areas to Watch (6)
Company is destroying shareholder value
Earnings declining -84.70%, profits shrinking
Company is losing money with a negative profit margin
Revenue growing slowly at 3.40% annually
Very low institutional interest at 1.34%
Micro-cap company with very limited liquidity and high volatility
INC Research Holdings Inc (INCR) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.49), Price/Book (0.30) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Profit Margin. Growth concerns include Revenue Growth at 3.40%, EPS Growth at -84.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -16.70%, Profit Margin at -29.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -16.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 3.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
INCR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
INCR's Price-to-Sales ratio of 0.49x sits near its historical average of 0.52x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 9% below its historical high of 0.54x set in Mar 2026, and 1% above its historical low of 0.49x in Mar 2026.
Compare INCR with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for INC Research Holdings Inc (INCR) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
INC Research Holdings Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 243M with 340% growth year-over-year. The company is currently unprofitable, posting a -29.2% profit margin.
Key Findings
Revenue growing at 340% YoY, reaching 243M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
Generating 4M in free cash flow and 6M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -29.2% profit margin. The path to breakeven will be the key catalyst.
Earnings fell 85% YoY while revenue grew 340%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Growth sustainability: can INC Research Holdings Inc maintain 340%+ revenue growth, or will competition slow it down?
Debt management: total debt of 179M is significantly higher than cash (51M). Monitor refinancing risk.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact INC Research Holdings Inc.
Bottom Line
INC Research Holdings Inc is a high-conviction growth story with revenue accelerating at 340% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -29.2% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About INC Research Holdings Inc(INCR)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Syneos Health, Inc., a contract research organization, provides various clinical development services for the medical device and biopharmaceutical industries in North America, Europe, the Middle East and Africa, Asia-Pacific, and Latin America. The company is headquartered in Raleigh, North Carolina.